ChemicalBook >> CAS DataBase List >>Valdecoxib

Valdecoxib

CAS No.
181695-72-7
Chemical Name:
Valdecoxib
Synonyms
BEXTRA;Valz;Valus;CS-592;SC 65872;Valecoxib;AKOS 92130;VALDECOXIB;Vatdecoxib;BEXTRA;SC 65872
CBNumber:
CB4754453
Molecular Formula:
C16H14N2O3S
Molecular Weight:
314.36
MDL Number:
MFCD00950568
MOL File:
181695-72-7.mol
MSDS File:
SDS
Last updated:2023-09-20 16:58:51

Valdecoxib Properties

Melting point 162-164°C
Boiling point 481.2±55.0 °C(Predicted)
Density 1.303±0.06 g/cm3(Predicted)
storage temp. room temp
solubility DMSO: >25mg/mL
pka 9.83±0.10(Predicted)
form powder
color white to off-white
InChI InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
InChIKey LNPDTQAFDNKSHK-UHFFFAOYSA-N
SMILES C1(S(N)(=O)=O)=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1
CAS DataBase Reference 181695-72-7(CAS DataBase Reference)
EWG's Food Scores 1
NCI Dictionary of Cancer Terms valdecoxib
FDA UNII 2919279Q3W
NCI Drug Dictionary Bextra
ATC code M01AH03

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS08,GHS09
Signal word  Warning
Hazard statements  H361d-H373-H410
Precautionary statements  P201-P202-P260-P273-P280-P308+P313
Hazard Codes  Xn,N
Risk Statements  63-48/22-51/53
Safety Statements  36/37-61
RIDADR  UN 3077 9 / PGIII
WGK Germany  3

Valdecoxib price More Price(39)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PZ0179 Valdecoxib ≥98% (HPLC) 181695-72-7 5mg $88.2 2024-03-01 Buy
Cayman Chemical 10006120 Valdecoxib ≥98% 181695-72-7 5mg $72 2024-03-01 Buy
Cayman Chemical 10006120 Valdecoxib ≥98% 181695-72-7 10mg $129 2024-03-01 Buy
Sigma-Aldrich PZ0179 Valdecoxib ≥98% (HPLC) 181695-72-7 25mg $581 2024-03-01 Buy
Cayman Chemical 10006120 Valdecoxib ≥98% 181695-72-7 25mg $301 2024-03-01 Buy
Product number Packaging Price Buy
PZ0179 5mg $88.2 Buy
10006120 5mg $72 Buy
10006120 10mg $129 Buy
PZ0179 25mg $581 Buy
10006120 25mg $301 Buy

Valdecoxib Chemical Properties,Uses,Production

Description

Valdecoxib is a second-generation COX-2 inhibitor, developed as a follow-up to celecoxib for the oral once-daily treatment of osteoarthritis, adult rheumatoid arthritis and menstrual pain. Valdecoxib is approximately 28,000-fold more selective against human recombinant COX-2 than human recombinant COX-1. In an ex viva human whole blood assay, the I&O values against COX-2 and COX-1 were respectively 0.89 PM and 25.4 FM. In animal models, valdecoxib possesses excellent oral activity as an antiinflammatory. In rats, valdecoxib potently inhibited carrageenan footpad edema and adjuvant-induced arthritis.

Chemical Properties

Valdecoxib is a white crystalline powder that is relatively insoluble in water (10 μg/mL) at 25°C and pH 7.0, soluble in methanol and ethanol, and freely soluble in organic solvents and alkaline (pH=12) aqueous solutions.

Originator

Pharmacia (Searle) (USA)

Uses

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. It is a potent and selective inhibitor of prostaglandin synthesis primarily through inhibition of COX-2. Valdecoxib is used to relieve some symptoms caused by arthritis (rheumatism), such as inflammation, swelling, stiffness, and joint pain.

Preparation

The step for the synthesis of valdecoxib: Deoxybenzoin is converted to the corresponding oxime by treatment with hydroxylamine under basic conditions with sodium acetate in aqueous ethanol or in toluene in presence of potassium hydroxide in absolute ethanol. The treatment of the oxime under nitrogen with two equivalents of butyllithium in tetrahydrofuran is followed by cyclization in ethyl acetate or acetic anhydride to the isoxazoline derivative. Finally, treatment of the isoxazoline with cold chlorosulfuric acid followed by reaction of the intermediate with aqueous ammonia afforded valdecoxib.
synthesis of valdecoxib

Definition

ChEBI: Valdecoxib is a member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. It has a role as a non-steroidal anti-inflammatory drug, a cyclooxygenase 2 inhibitor, a non-narcotic analgesic, an antirheumatic drug and an antipyretic. It is a member of isoxazoles and a sulfonamide.

brand name

Bextra (Searle).

General Description

Valdecoxib (VCX) is a diaryl substituted isoxazole compound. It comprises of sulfonyl propanamide and is a metabolite of parecoxib.

Biochem/physiol Actions

Valdecoxib is reported to elicit anti-inflammatory, analgesic and antipyretic functionality. It acts as a substrate for the liver enzyme cytochrome P450 2C9(CYP2C9) and cytochrome P450 3A4 (CYP3A4).

Pharmacokinetics

Valdecoxib is freely soluble in alkaline aqueous solutions. At recommended doses, the mean oral bioavailability for valdecoxib is 83%, and the time to peak concentration is approximately 3 hours. Time to peak plasma concentration was delayed by 1 to 2 hours when administered with a high-fat meal. Protein binding is very high at 98%. Valdecoxib exhibits linear pharmacokinetics over the usual clinical dose range. Valdecoxib is extensively metabolized in humans. The primary metabolite for valdecoxib involved CYP2C9 hydroxylation of the 5-Me group, which was further metabolized to the inactive carboxylate, and N-hydroxylation at the sulfonamide moiety. Oxidative breakdown of the N-hydroxy sulfonamide function group led to the formation of the corresponding sulfinic acid and sulfonic acid metabolites. The O-and N-glucuronides were the major urinary metabolites. Only 3% of the administered dose was recovered in urine as unchanged valdecoxib.

Clinical Use

Valdecoxib is approved for the relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea. Valdecoxib is contraindicated for the treatment of postoperative pain immediately following coronary artery bypass graft surgery.

storage

Store at RT

Mode of action

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. The mechanism of action is believed to be due to inhibition of prostaglandin synthesis primarily through inhibition of cyclooxygenase-2 (COX-2). At therapeutic plasma concentrations in humans valdecoxib does not inhibit cyclooxygenase-1 (COX-1).

Clinical claims and research

Valdecoxib is a substrate of CYP3A4 but no metabolism interference was seen with commonly used synthetic narcotics, alfentanil and fentanyl. Clinical studies have shown that valdecoxib is as effective as naproxen in treating osteoarthritis, rheumatoid arthritis and dysmenornhoea. The efficacy of valdecoxib was also demonstrated in managing postoperative pain (oral and orthopedic surgery) with effective analgesia and time to rescue medication superior to those obtained with rofecoxib. Several clinical trials showed that valdecoxib has a better upper gastrointestinal safety profile compared to naproxen, ibuprofen or diclofenac and does not affect platelet function. Less abdominal pain, dyspepsia and constipation were observed with valdecoxib than with naproxen. Valdecoxib is contraindicated in patients with a history of allergic reactions to sulfonamides due to reported anaphylactic and skin reactions.

References

[1] talley j j, brown d l, carter j s, et al. 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of cox-2. journal of medicinal chemistry, 2000, 43(5): 775-777.
[2] nussmeier n a, whelton a a, brown m t, et al. complications of the cox-2 inhibitors parecoxib and valdecoxib after cardiac surgery. new england journal of medicine, 2005, 352(11): 1081-1091.

37928-17-9
181695-72-7
Synthesis of Valdecoxib from 5-Methyl-3,4-diphenylisoxazole
Global( 368)Suppliers
Supplier Tel Email Country ProdList Advantage
Hangzhou Benoy Chemical Co., Ltd
+8617342059697 sales@benoychem.com China 315 58
Hebei Mojin Biotechnology Co., Ltd
+86-13288715578 +86-13231137666 sales@hbmojin.com China 12409 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21703 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714 fandachem@gmail.com China 9359 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682 bruce@xrdchem.cn CHINA 566 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29919 58
Shanghai Arbor Chemical Co., Ltd.
021-60451682 act@arborchemical.com CHINA 906 58
Hangzhou Cyanochem Co., Ltd.
+86 17788583750 sales@cyanochem.com CHINA 283 58
Hubei Jusheng Technology Co.,Ltd.
18871490254 linda@hubeijusheng.com CHINA 28180 58

View Lastest Price from Valdecoxib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
4-?(5-?Methyl-?3-?phenylisoxazol-?4-?yl)?benzenesulfonamide pictures 2023-09-20 4-?(5-?Methyl-?3-?phenylisoxazol-?4-?yl)?benzenesulfonamide
181695-72-7
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mojin Biotechnology Co., Ltd
Valdecoxib pictures 2023-08-15 Valdecoxib
181695-72-7
US $0.00 / KG 1KG 99% 50000KG/month Hebei Mojin Biotechnology Co., Ltd
Valdecoxib pictures 2023-03-18 Valdecoxib
181695-72-7
US $10.00 / KG 1KG 99% 10 mt Hebei Guanlang Biotechnology Co., Ltd.
  • Valdecoxib pictures
  • Valdecoxib
    181695-72-7
  • US $0.00 / KG
  • 99%
  • Hebei Mojin Biotechnology Co., Ltd
  • Valdecoxib pictures
  • Valdecoxib
    181695-72-7
  • US $10.00 / KG
  • 99%
  • Hebei Guanlang Biotechnology Co., Ltd.

Valdecoxib Spectrum

VALDECOXIB 4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFONAMIDE AKOS 92130 BEXTRA(VALDECOXIB) Bextra, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenefulfonamide 4-(5-methyl-3-phenyl-oxazol-4-yl)benzenesulfonamide Bextra, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide SC 65872 Valecoxib Valus Valz 4-(5-Methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide Parecoxib SodiuM interMediate B Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- Valdecoxib Solution, 100ppm Valdecoxib (This product is only available in Japan.) Parecoxib Impurity 4 Parecoxib Sodium-7 Valdecoxib - SC 65872 | Bextra Parecoxib sodium intermediate BEXTRA;SC 65872 Parecoxib Impurity 7(Valdecoxib) CS-592 Parecoxib Impurity E: Vardecoxib 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfomide Valdecoxib Parecoxib Sodium intermediates Valdecoxib, 98%, a COX-2 selective inhibitor 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide Vatdecoxib 4-(5-Methyl-3-phenyl-4-isooxazolyl)benzenesulfonamide VALDECOXIB ISO 9001:2015 REACH 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenefulfonamide parecoxib sulfonamide Valdecoxib (SC65872) TIANFU-CHEM Benzenesulfonamide,4-(5-methyl-3-phenyl-4-isoxazolyl)- BEXTRA PARECOXIB SULFOMIDE Valdecoxib(Parecoxib Sodium Impurity 8) Parecoxib Impurity 7 CRS 181695-72-7 181695-72-1 C1614N2O3S SC-65872, YM-974 Intermediates & Fine Chemicals Pharmaceuticals Amines Aromatics Heterocycles Sulfur & Selenium Compounds Active Pharmaceutical Ingredients Osteoarthritis and Rheumatoid Arthritis